Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer
Authors
Keywords
-
Journal
ESMO Open
Volume 7, Issue 5, Pages 100561
Publisher
Elsevier BV
Online
2022-09-07
DOI
10.1016/j.esmoop.2022.100561
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 284P Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
- (2021) S-A. Im et al. ANNALS OF ONCOLOGY
- Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
- (2021) Aykut Bahçeci et al. CANCER INVESTIGATION
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
- (2019) Filippo Montemurro et al. EUROPEAN JOURNAL OF CANCER
- T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
- (2019) Benedetta Conte et al. Clinical Breast Cancer
- Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
- (2019) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
- (2019) Max Hardy-Werbin et al. Scientific Reports
- Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine
- (2019) Natansh D. Modi et al. Clinical Breast Cancer
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer
- (2018) Virginia F. Borges et al. JAMA Oncology
- Pyrotinib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
- (2017) Patrizia Vici et al. Oncotarget
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
- (2014) Véronique Diéras et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now